FDA Approves ViiV’s Triumeq PD for Children With HIV

ViiV Healthcare says FDA approved Triumeq PD, the first dispersible single-tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV.

• About 1.7m children globally were living with HIV in 2020, according to UNAIDS
• ViiV is majority-owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders

NOTE

• Pfizer Inc. fell 0.1% in postmarket trading to $52.40 as of 5:14 p.m. New York time
• Shionogi & Co. fell 1.4% to 7,563.00 yen as of last close
• GlaxoSmithKline Plc rose 1.2% to GBp1,660.80 as of last close

To view the source of this information, click here

To contact the reporter on this ...